Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.

A Tale of Two Pharmaceuticals: SG&A Expenses Over Time

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. This analysis compares the SG&A expenses of Amneal Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc. from 2014 to 2023. Over this period, Amneal Pharmaceuticals has seen a significant increase in its SG&A expenses, growing by approximately 408% from 2014 to 2023. In contrast, Xenon Pharmaceuticals, while also experiencing growth, has maintained a more modest increase of around 747% over the same period.

Amneal's expenses peaked in 2023, reaching nearly five times their 2014 levels, reflecting its aggressive expansion and market penetration strategies. Meanwhile, Xenon's expenses, though smaller in absolute terms, have shown a steady upward trend, indicating its strategic investments in research and development. This comparison highlights the diverse strategies employed by pharmaceutical companies in managing operational costs.